News
Ambrosia's sweet $100m round, and other biofinancings
Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
News
Immunovant's thyroid eye disease drug flunks pivotal trials
Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
R&D
Redefining drug discovery: Morocco’s biotech strategy for in...
Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.
News
AZ claims another win for Imfinzi in frontline liver cancer
AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
News
Alzheimer's biotech Korsana to go public via reverse merger
By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
